ARENA PHARMACEUTICALS INC Form 8-K October 26, 2004

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 26, 2004

ARENA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

DELAWARE (State or Other Jurisdiction of Incorporation) 000-31161 (Commission File Number) 23-2908305 (I.R.S. Employer Identification No.)

6166 Nancy Ridge Drive, San Diego, California 92121

(Address of Principal Executive Offices) (Zip Code)


(858) 453-7200

23-2908305

(Registrant s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)



23-2908305

Item 8.01. Other Events.

On October 26, 2004, Arena Pharmaceuticals, Inc. issued a press release announcing that Arena has achieved a pre-clinical development milestone under their collaboration with Merck & Co., Inc., a New Jersey corporation, as a result of Merck selecting an Arena-discovered compound for advancement in pre-clinical development. The milestone achievement triggered a \$1 million payment to Arena. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

99.1

Press release issued October 26, 2004, announcing that Arena has achieved a pre-clinical development milestone under their collaboration with Merck as a result of Merck selecting an Arena-discovered compound for advancement in pre-clinical development.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 26, 2004 Arena Pharmaceuticals, Inc., a Delaware corporation

By: /s/ Jack Lief

Jack Lief

President & Chief Executive Officer

2

23-2908305

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release issued October 26, 2004, announcing that Arena has achieved a pre-clinical development milestone under their collaboration with Merck as a result of Merck selecting an Arena-discovered compound for advancement in pre-clinical development.
	3

23-2908305 4